Cabometyx
Named-patient access overview. Cabometyx is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Cabometyx (cabozantinib) is an oral multi-kinase inhibitor developed by Exelixis that targets VEGFR, MET, AXL, and RET. The US Food and Drug Administration first approved Cabometyx in April 2016 for advanced renal cell carcinoma, with subsequent indications added for hepatocellular carcinoma previously treated with sorafenib, locally advanced or metastatic differentiated thyroid cancer refractory to radioactive iodine, and previously treated advanced neuroendocrine tumours. The drug is given as a once-daily oral tablet (typically 60 mg on an empty stomach) and is initiated and monitored by a medical oncologist.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Cabometyx
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Cabometyx is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Cabometyx in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Cabometyx
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.